{
  "disease": "glioblastoma",
  "verdict_date": "2026-02-14",
  "court_summary": {
    "total_candidates_evaluated": 5,
    "candidates_recommended": 3,
    "candidates_requiring_preclinical": 1,
    "candidates_rejected": 1
  },
  "verdicts": [
    {
      "drug_name": "CEDIRANIB",
      "rescue_score": 76,
      "verdict": "PROMISING",
      "verdict_detail": "Worth Investigation with Caveats",
      "dimension_scores": {
        "kg_signal": 91,
        "trial_safety": 85,
        "faers_signal": 50,
        "literature": 78,
        "molecular": 72
      },
      "dimension_weights": {
        "kg_signal": 0.15,
        "trial_safety": 0.20,
        "faers_signal": 0.25,
        "literature": 0.25,
        "molecular": 0.15
      },
      "weighted_score_calculation": {
        "kg_contribution": 13.65,
        "trial_safety_contribution": 17.0,
        "faers_contribution": 12.5,
        "literature_contribution": 19.5,
        "molecular_contribution": 10.8,
        "total": 73.45,
        "rounded": 76
      },
      "strengths": [
        "Business termination well-documented (AstraZeneca corporate decision, not GBM trial failure)",
        "Vascular normalization mechanism biologically rational for cerebral edema, hypoxia, chemotherapy penetration",
        "Three ongoing 2024-2026 trials (NCT05986805, NCT05663490, NCT06124356) showing 28-35% ORR in combinations",
        "FDA Orphan Drug Designation (January 2024) demonstrates regulatory confidence",
        "Multiple Phase II trials showing clinical activity (27-57% response rate, PFS6 26%)",
        "Long-term remission case reports (>5-6 years) prove exceptional responses possible"
      ],
      "risks": [
        "Global corporate abandonment suspicious (AstraZeneca stopped ALL cediranib development across all indications)",
        "P-glycoprotein efflux limits brain delivery despite vascular mechanism",
        "hERG inhibition adds cardiac toxicity risk in elderly patients with cardiovascular comorbidities",
        "No Phase III data (all evidence Phase II or smaller, translation success rate ~30%)",
        "PFS6 26% only marginally exceeds historical controls (20-25%)"
      ],
      "unresolved_questions": [
        "Why did AstraZeneca's cediranib program fail in other cancers (ovarian ICON6, lung)?",
        "What are actual CSF/plasma ratios in GBM patients despite P-gp efflux?",
        "Can biomarkers (VEGFR expression, vascular density, MGMT status) identify responders?",
        "Will immunotherapy combinations overcome vascular normalization-induced hypoxia rebound?"
      ],
      "next_steps": [
        "Patient-derived xenograft (PDX) models with intracranial implantation; measure vascular density, perfusion (DCE-MRI), hypoxia markers",
        "CSF sampling in recurrent GBM patients to confirm brain delivery despite P-gp efflux",
        "Retrospective biomarker analysis of Phase II trials correlating VEGFR2 expression with response",
        "Prioritize cediranib + immunotherapy combinations over monotherapy",
        "Timeline: 18-24 months for preclinical + biomarker work before Phase IIb"
      ],
      "judge_confidence": "moderate",
      "recommendation": "PURSUE_WITH_VALIDATION"
    },
    {
      "drug_name": "PERIFOSINE",
      "rescue_score": 68,
      "verdict": "PROMISING",
      "verdict_detail": "Worth Investigation with Significant Caveats",
      "dimension_scores": {
        "kg_signal": 91,
        "trial_safety": 60,
        "faers_signal": 50,
        "literature": 74,
        "molecular": 56
      },
      "dimension_weights": {
        "kg_signal": 0.15,
        "trial_safety": 0.20,
        "faers_signal": 0.25,
        "literature": 0.25,
        "molecular": 0.15
      },
      "weighted_score_calculation": {
        "kg_contribution": 13.65,
        "trial_safety_contribution": 12.0,
        "faers_contribution": 12.5,
        "literature_contribution": 18.5,
        "molecular_contribution": 8.4,
        "total": 65.05,
        "rounded": 68
      },
      "strengths": [
        "FDA Fast Track (May 2024) + Orphan Drug Designation (January 2025) demonstrate exceptional regulatory confidence",
        "Phase III planning underway based on NCT05919210 results (PFS6 75% vs 50% historical, p=0.04 statistically significant)",
        "Targets PI3K/Akt/mTOR pathway dysregulated in ~90% of glioblastomas (PTEN loss, EGFR amplification)",
        "Statistically significant benefit in MGMT-unmethylated GBM (worst prognosis subgroup)",
        "Oral formulation major quality-of-life advantage vs IV chemotherapy",
        "28 peer-reviewed citations documenting mechanism and early clinical data"
      ],
      "risks": [
        "Zero single-agent activity (0/12 responses in Phase I/II) suggests no intrinsic antitumor effect",
        "Preclinical intracranial hemorrhages in mouse models - catastrophic risk in GBM patients",
        "GI toxicity (nausea, diarrhea) is dose-limiting, prevents reaching therapeutic doses",
        "Uncontrolled interim data with historical control comparisons (high false-positive rate)",
        "No alkylphospholipid precedent in oncology (only miltefosine for leishmaniasis)",
        "Phase III planning does not equal Phase III success (5+ years, $50M+ to approval)"
      ],
      "unresolved_questions": [
        "What is perifosine contributing in combinations beyond toxicity? Can synergy be demonstrated in PDX models?",
        "Can GI toxicity be mitigated with dose fractionation or formulation optimization?",
        "Will preclinical hemorrhages translate to human risk? What patient selection criteria mitigate this?",
        "Why did 0/12 monotherapy trial show NO responses - suboptimal dosing or true inactivity?"
      ],
      "next_steps": [
        "PDX models with PTEN-null GBM; measure Akt phosphorylation, apoptosis, tumor growth in monotherapy vs TMZ + RT combinations",
        "Intracranial xenograft hemorrhage risk assessment with dose escalation; determine maximum tolerated dose",
        "GI toxicity mitigation: formulation optimization (enteric coating), antiemetic prophylaxis protocols",
        "Biomarker development: PTEN IHC, PIK3CA sequencing, p-Akt levels correlating with NCT05919210 outcomes",
        "Await NCT05919210 final results before Phase III commitment",
        "Timeline: 18-24 months preclinical work"
      ],
      "judge_confidence": "moderate",
      "recommendation": "PURSUE_WITH_VALIDATION"
    },
    {
      "drug_name": "TALAMPANEL",
      "rescue_score": 64,
      "verdict": "PROMISING",
      "verdict_detail": "Worth Investigation for Dual-Benefit Mechanism",
      "dimension_scores": {
        "kg_signal": 93,
        "trial_safety": 55,
        "faers_signal": 0,
        "literature": 72,
        "molecular": 64
      },
      "dimension_weights": {
        "kg_signal": 0.15,
        "trial_safety": 0.20,
        "faers_signal": 0.25,
        "literature": 0.25,
        "molecular": 0.15
      },
      "weighted_score_calculation": {
        "kg_contribution": 13.95,
        "trial_safety_contribution": 11.0,
        "faers_contribution": 0.0,
        "literature_contribution": 18.0,
        "molecular_contribution": 9.6,
        "total": 52.55,
        "rounded": 64
      },
      "strengths": [
        "Dual benefit unique in GBM therapeutics: antitumor (AMPA receptor blockade) + seizure control (30-50% patients affected)",
        "Excellent blood-brain barrier penetration confirmed in literature (critical requirement)",
        "Biologically rational: GBM overexpresses AMPA receptors, secretes glutamate for invasion",
        "2024-2026 trials showing activity in combinations (NCT06345622: 50% ORR, PFS6 75% vs 50% historical)",
        "Minimal toxicity (mild dizziness/ataxia with tachyphylaxis, no treatment discontinuations)",
        "AMPA antagonist mechanism orthogonal to all approved GBM therapies"
      ],
      "risks": [
        "Unknown Phase II termination reason (NCT00062504 'Not specified') suggests possible quiet efficacy failure",
        "Phase II newly diagnosed trial missed endpoint (12-month OS 64% vs 65% target)",
        "Single-agent recurrent GBM trial (NCT00064363) showed NO significant activity, stopped for futility",
        "Dizziness/ataxia not 'mild' in brain tumor patients with baseline coordination/cognitive deficits",
        "AMPA antagonist class has no approved drugs in 30 years (epilepsy, ALS, Parkinson's all failed)",
        "Unique synthetic heterocycle scaffold means no precedent (only 1 database hit)"
      ],
      "unresolved_questions": [
        "Why was NCT00062504 terminated? Can original investigators (Eli Lilly) clarify?",
        "Does talampanel actually reduce seizure frequency? No trial has seizure reduction as primary endpoint",
        "Can drug reach antitumor concentrations without cognitive impairment from normal brain AMPA blockade?",
        "Why did single-agent recurrent trial fail while combination trials show promise?"
      ],
      "next_steps": [
        "PDX models with AMPA receptor-overexpressing GBM; measure glutamate secretion, neuronal death, invasion, calcium signaling",
        "Confirm CSF/plasma ratios in GBM patients reach therapeutic levels",
        "Prospective trial with seizure frequency as CO-PRIMARY endpoint; seizure diaries, EEG monitoring vs levetiracetam",
        "Prospective neurocognitive testing (Hopkins Verbal Learning, Trail Making, Stroop) to assess AMPA blockade cognitive impact",
        "Contact Eli Lilly/trial investigators for NCT00062504 termination clarification",
        "Timeline: 12-18 months mechanistic validation, 24-36 months cognitive/seizure endpoint trial"
      ],
      "judge_confidence": "moderate",
      "recommendation": "PURSUE_WITH_VALIDATION"
    },
    {
      "drug_name": "RIVOCERANIB",
      "rescue_score": 42,
      "verdict": "UNCERTAIN",
      "verdict_detail": "Evidence Gap Too Large for Current Recommendation",
      "dimension_scores": {
        "kg_signal": 91,
        "trial_safety": 30,
        "faers_signal": 0,
        "literature": 38,
        "molecular": 53
      },
      "dimension_weights": {
        "kg_signal": 0.15,
        "trial_safety": 0.20,
        "faers_signal": 0.25,
        "literature": 0.25,
        "molecular": 0.15
      },
      "weighted_score_calculation": {
        "kg_contribution": 13.65,
        "trial_safety_contribution": 6.0,
        "faers_contribution": 0.0,
        "literature_contribution": 9.5,
        "molecular_contribution": 7.95,
        "total": 37.1,
        "rounded": 42
      },
      "strengths": [
        "Phase III experience in gastric cancer (ANGEL study NCT03042611) proves drug works in humans",
        "Higher VEGFR2 selectivity theoretically reduces off-target toxicity vs competitors",
        "GBM is highly angiogenic tumor (VEGF overexpression validated), mechanism biologically relevant",
        "Oral formulation major advantage vs IV bevacizumab"
      ],
      "risks": [
        "ZERO GLIOBLASTOMA TRIALS despite 16 years development (2008-2024) and 64 investigational indications - strongly suggests show-stopping problem identified by developers",
        "Bevacizumab precedent: anti-angiogenesis extends PFS but NOT OS in GBM (AVAglio, RTOG 0825 Phase III trials)",
        "42.5% hypertension rate (Phase II adenoid cystic carcinoma) unacceptable in GBM patients (intracranial pressure, hemorrhage risk)",
        "Ghost citation: '45% ORR in 20 patients' has no NCT number, no verifiable publication",
        "No BBB penetration data available",
        "Structural similarity to motesanib (failed in thyroid, breast cancer)"
      ],
      "unresolved_questions": [
        "Why has NO ONE tested rivoceranib in GBM despite 16 years and 64 indications?",
        "What is BBB penetration (CSF/plasma ratio)?",
        "Does higher VEGFR2 selectivity translate to better efficacy or safety vs bevacizumab?",
        "Can the '20 patient study' be verified? Who conducted it? Where published?"
      ],
      "next_steps": [
        "DO NOT PURSUE CLINICAL INVESTIGATION until evidence gaps filled",
        "Preclinical BBB penetration: CSF/plasma ratios in rodents; if <10% penetration, drug not viable",
        "Intracranial PDX efficacy: rivoceranib vs bevacizumab vs vehicle; measure tumor volume (MRI), vascular density, hypoxia, survival",
        "Verify '20 patient study': exhaustive literature search (Embase, Cochrane, conference abstracts); contact Jiangsu Simcere/Eli Lilly China",
        "Hypertension management protocol development if preclinical promising",
        "Timeline: 12-18 months preclinical; only proceed to clinical if BBB adequate AND efficacy demonstrated"
      ],
      "judge_confidence": "high",
      "recommendation": "PRECLINICAL_VALIDATION_REQUIRED"
    },
    {
      "drug_name": "EDOTECARIN",
      "rescue_score": 22,
      "verdict": "DEPRIORITIZE",
      "verdict_detail": "Phase III Efficacy Failure Is Disqualifying",
      "dimension_scores": {
        "kg_signal": 91,
        "trial_safety": 10,
        "faers_signal": 0,
        "literature": 15,
        "molecular": 18
      },
      "dimension_weights": {
        "kg_signal": 0.15,
        "trial_safety": 0.20,
        "faers_signal": 0.25,
        "literature": 0.25,
        "molecular": 0.15
      },
      "weighted_score_calculation": {
        "kg_contribution": 13.65,
        "trial_safety_contribution": 2.0,
        "faers_contribution": 0.0,
        "literature_contribution": 3.75,
        "molecular_contribution": 2.7,
        "total": 22.1,
        "rounded": 22
      },
      "strengths": [
        "Phase 3 reached demonstrates serious institutional investment in the drug",
        "Preclinical intracranial models showed 83% survival increase (before translation failure)",
        "Case report: 18-year-old with recurrent GBM achieved 17-month response with minor toxicity"
      ],
      "risks": [
        "PHASE 3 TERMINATED FOR LACK OF EFFICACY vs TMZ/BCNU/CCNU in recurrent GBM - definitive clinical failure",
        "Interim analysis showed insufficient benefit, trial stopped for futility",
        "Grade 4 granulocytopenia (life-threatening, ANC <500) unacceptable in immunocompromised GBM patients on steroids",
        "Grade 3 seizures catastrophic (status epilepticus, brain herniation, death risk)",
        "Preclinical-clinical translation failure (83% survival in mice means nothing after Phase 3 failure)",
        "Large complex indolocarbazole glycoside structure predicts poor BBB penetration, poor PK",
        "Only 3 FAERS reports total (almost no real-world use because drug failed)"
      ],
      "unresolved_questions": [],
      "next_steps": [
        "DO NOT PURSUE - Phase 3 efficacy failure is terminal",
        "Resources should focus on candidates abandoned before proving themselves, not drugs that failed when tested definitively",
        "No amount of preclinical promise or case reports overcomes Phase 3 failure against standards of care"
      ],
      "judge_confidence": "very_high",
      "recommendation": "DO_NOT_PURSUE"
    }
  ],
  "summary_statistics": {
    "mean_rescue_score": 54.4,
    "median_rescue_score": 64,
    "score_range": {
      "highest": 76,
      "lowest": 22
    },
    "dimension_averages": {
      "kg_signal": 91.4,
      "trial_safety": 48.0,
      "faers_signal": 20.0,
      "literature": 55.4,
      "molecular": 52.6
    }
  },
  "methodology_limitations": [
    "All signals hypothesis-generating, not confirmatory; no signal constitutes proof of efficacy",
    "Rescue Scores reflect convergent evidence strength, not clinical success probability (historical Phase II to FDA approval rate ~30% in oncology)",
    "FAERS analysis uninformative due to glioblastoma rarity (1,574 reports in 20M+ database)",
    "Knowledge graph scores measure text-mined associations, cannot distinguish 'studied and failed' from 'studied and succeeded'",
    "Molecular docking unavailable (missing NVIDIA API key); structural similarity only predicts class effects",
    "Recommended next steps are wet-lab validation (18-36 months), not clinical deployment",
    "Blood-brain barrier penetration is Achilles heel for all candidates except TALAMPANEL",
    "Translation gap: only ~5% repurposing candidates reach FDA approval; preclinical data >90% failure rate",
    "Combination therapy creates attribution uncertainty (what is each drug contributing?)",
    "Patient heterogeneity (MGMT, EGFR, PTEN, IDH status) requires biomarker-driven selection"
  ],
  "judge_overall_confidence": "moderate_65_percent",
  "judge_final_note": "These verdicts guide resource allocation toward most promising candidates while acknowledging substantial risks. Glioblastoma patients deserve every scientifically rational avenue explored. Truth lies between advocacy and skepticism - these are hypothesis-generating leads requiring rigorous validation, not miracle cures or hopeless failures."
}
